QYResearch: In 2016, global revenue of bacterial vaginosis drug is nearly 772 M USD

QYResearch

Bacterial Vaginosis Drug is used for the treatment of Bacterial Vaginosis (BV), which also known as vaginal bacteriosis or Gardnerella vaginitis, a disease of the vagina caused by excessive bacteria.

In the last several years, global market of bacterial vaginosis drug developed smoothly, with an average growth rate of 3.01%. In 2016, global revenue of bacterial vaginosis drug is nearly 772 M USD.

The classification of bacterial vaginosis drug includes Rx and OTC, and the proportion of OTC in 2016 is about 72%.

According to QYResearch, Bacterial vaginosis drug is widely sold in hospital, pharmacy and other field. The most proportion of bacterial vaginosis drug is sold in pharmacy, and the revenue in 2016 is about 423 M USD.

USA region is the largest supplier of bacterial vaginosis drug, with a revenue market share nearly 32% in 2016. Europe is the second largest supplier of Bacterial Vaginosis Drug, enjoying revenue market share nearly 30% in 2016.

USA and Europe are the largest consumption places, with the consumption market share nearly 28% in 2016.

Full Report Link: http://www.qyresearchglobal.com/goods-1027455.html

This article was first released by QYResearch analyst, if reproduced, please indicate the        source.

Marketing: sales@qyresearch.com

Media Contact: press@qyresearch.com